Document Detail


SGLT2 inhibition--a novel strategy for diabetes treatment.
MedLine Citation:
PMID:  20508640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhibiting sodium-glucose co-transporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. Genetic mutations in the kidney-specific SGLT2 isoform that result in benign renal glycosuria, as well as preclinical and clinical studies with SGLT2 inhibitors in type 2 diabetes, support the potential of this approach. These investigations indicate that elevating renal glucose excretion by suppressing SGLT2 can reduce plasma glucose levels, as well as decrease weight. Although data from ongoing Phase III trials of these agents are needed to more fully assess safety, results suggest that the beneficial effects of SGLT2 inhibition might be achieved without exerting significant side effects--an advantage over many current diabetes medications. This article discusses the role of SGLT2 in glucose homeostasis and the evidence available so far on the therapeutic potential of blocking these transporters in the treatment of diabetes.
Authors:
Edward C Chao; Robert R Henry
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2010-05-28
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  9     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-01     Completed Date:  2010-07-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  551-9     Citation Subset:  IM    
Affiliation:
Section of Endocrinology, Metabolism and Diabetes, VA San Diego Healthcare System and University of California, San Diego School of Medicine, 3350 La Jolla Village Drive, 111 G San Diego, California 92161, USA. edward.chao@va.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy
Drug Design
Glucose / metabolism
Humans
Hypoglycemic Agents / adverse effects,  pharmacology*,  therapeutic use*
Kidney / metabolism
Oligonucleotides, Antisense / therapeutic use
Sodium-Glucose Transporter 2 / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Oligonucleotides, Antisense; 0/SLC5A2 protein, human; 0/Sodium-Glucose Transporter 2; 50-99-7/Glucose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Case report: a black and white twin.
Next Document:  Nucleosome occupancy landscape and dynamics at mouse recombination hotspots.